AstraZeneca Historical Income Statement

AZN Stock

10,468 100.00 0.95%

Historical analysis of AstraZeneca PLC income statement accounts such as Interest Expense of 1.7 B, Total Revenue of 24.2 B or Gross Profit of 19.9 B can show how well AstraZeneca PLC performed in making a profits. Evaluating AstraZeneca PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AstraZeneca PLC's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About AstraZeneca Income Statement Analysis

AstraZeneca PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AstraZeneca PLC shareholders. The income statement also shows AstraZeneca investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AstraZeneca PLC Income Statement Chart

At present, AstraZeneca PLC's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 11.5 B, whereas Gross Profit is forecasted to decline to about 19.9 B.

Total Revenue Other Operating Expenses Ebit

Total Revenue

Total revenue comprises all receipts AstraZeneca PLC generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AstraZeneca PLC. It is also known as AstraZeneca PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from AstraZeneca PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Interest Expense	1.3B	1.3B	1.6B	1.7B
Depreciation And Amortization	4.1B	5.3B	4.9B	5.2B

Interest Expense Depreciation And Amortization

AstraZeneca PLC income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Cost Of Revenue	Minority Interest	Selling And Marketing Expenses	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.55	0.69	0.65	0.73	0.02	0.03	0.85	0.34	0.87	-0.02	-0.43	0.03	-0.18	-0.1	0.56	-0.12	0.73	0.44	0.06	0.14	0.59	0.64	-0.49
Interest Expense	0.55		0.43	0.43	0.42	0.11	0.11	0.75	0.24	0.59	0.01	-0.88	0.09	-0.23	-0.26	0.24	0.4	0.32	0.61	0.12	0.21	0.59	0.47	-0.46
Total Revenue	0.69	0.43		0.98	0.96	0.39	0.4	0.76	0.66	0.77	0.33	-0.26	0.4	0.06	-0.04	0.76	-0.32	0.89	0.26	-0.08	0.24	0.3	0.64	-0.15
Gross Profit	0.65	0.43	0.98		0.89	0.52	0.54	0.73	0.77	0.75	0.47	-0.21	0.53	0.19	-0.06	0.62	-0.31	0.84	0.36	0.06	0.16	0.38	0.52	-0.22
Other Operating Expenses	0.73	0.42	0.96	0.89		0.1	0.12	0.76	0.43	0.77	0.05	-0.36	0.12	-0.2	-0.03	0.85	-0.29	0.95	0.19	-0.2	0.32	0.26	0.75	-0.09
Operating Income	0.02	0.11	0.39	0.52	0.1		1.0	0.14	0.92	0.14	0.99	0.29	0.99	0.83	-0.01	-0.11	-0.17	0.02	0.24	0.32	-0.21	0.18	-0.2	-0.18
Ebit	0.03	0.11	0.4	0.54	0.12	1.0		0.16	0.93	0.16	0.99	0.29	0.99	0.83	-0.02	-0.1	-0.18	0.04	0.26	0.33	-0.21	0.19	-0.19	-0.19
Research Development	0.85	0.75	0.76	0.73	0.76	0.14	0.16		0.37	0.96	0.09	-0.56	0.14	-0.12	-0.4	0.66	-0.18	0.73	0.61	0.16	0.04	0.68	0.79	-0.65
Ebitda	0.34	0.24	0.66	0.77	0.43	0.92	0.93	0.37		0.37	0.89	0.13	0.92	0.67	0.05	0.12	-0.18	0.33	0.27	0.22	-0.03	0.26	0.02	-0.16
Total Operating Expenses	0.87	0.59	0.77	0.75	0.77	0.14	0.16	0.96	0.37		0.12	-0.39	0.15	-0.07	-0.34	0.69	-0.35	0.8	0.61	0.2	-0.04	0.7	0.77	-0.68
Income Before Tax	-0.02	0.01	0.33	0.47	0.05	0.99	0.99	0.09	0.89	0.12		0.39	0.99	0.87	-0.02	-0.13	-0.24	-0.02	0.21	0.34	-0.28	0.16	-0.23	-0.19
Total Other Income Expense Net	-0.43	-0.88	-0.26	-0.21	-0.36	0.29	0.29	-0.56	0.13	-0.39	0.39		0.3	0.58	0.15	-0.23	-0.54	-0.29	-0.43	0.07	-0.41	-0.38	-0.45	0.2
Net Income	0.03	0.09	0.4	0.53	0.12	0.99	0.99	0.14	0.92	0.15	0.99	0.3		0.78	0.05	-0.08	-0.17	0.04	0.24	0.22	-0.25	0.13	-0.2	-0.15
Income Tax Expense	-0.18	-0.23	0.06	0.19	-0.2	0.83	0.83	-0.12	0.67	-0.07	0.87	0.58	0.78		-0.16	-0.3	-0.35	-0.23	0.03	0.59	-0.24	0.14	-0.34	-0.19
Selling General Administrative	-0.1	-0.26	-0.04	-0.06	-0.03	-0.01	-0.02	-0.4	0.05	-0.34	-0.02	0.15	0.05	-0.16		-0.14	0.16	-0.06	-0.35	-0.49	0.29	-0.55	-0.44	0.65
Cost Of Revenue	0.56	0.24	0.76	0.62	0.85	-0.11	-0.1	0.66	0.12	0.69	-0.13	-0.23	-0.08	-0.3	-0.14		-0.42	0.84	0.02	-0.34	0.28	0.15	0.9	-0.1
Minority Interest	-0.12	0.4	-0.32	-0.31	-0.29	-0.17	-0.18	-0.18	-0.18	-0.35	-0.24	-0.54	-0.17	-0.35	0.16	-0.42		-0.4	-0.02	-0.26	0.18	-0.09	-0.24	0.23
Selling And Marketing Expenses	0.73	0.32	0.89	0.84	0.95	0.02	0.04	0.73	0.33	0.8	-0.02	-0.29	0.04	-0.23	-0.06	0.84	-0.4		0.28	-0.11	0.26	0.37	0.75	-0.2
Net Income From Continuing Ops	0.44	0.61	0.26	0.36	0.19	0.24	0.26	0.61	0.27	0.61	0.21	-0.43	0.24	0.03	-0.35	0.02	-0.02	0.28		0.51	-0.25	0.79	0.21	-0.79
Tax Provision	0.06	0.12	-0.08	0.06	-0.2	0.32	0.33	0.16	0.22	0.2	0.34	0.07	0.22	0.59	-0.49	-0.34	-0.26	-0.11	0.51		-0.14	0.64	-0.13	-0.62
Net Interest Income	0.14	0.21	0.24	0.16	0.32	-0.21	-0.21	0.04	-0.03	-0.04	-0.28	-0.41	-0.25	-0.24	0.29	0.28	0.18	0.26	-0.25	-0.14		-0.04	0.27	0.43
Interest Income	0.59	0.59	0.3	0.38	0.26	0.18	0.19	0.68	0.26	0.7	0.16	-0.38	0.13	0.14	-0.55	0.15	-0.09	0.37	0.79	0.64	-0.04		0.44	-0.88
Reconciled Depreciation	0.64	0.47	0.64	0.52	0.75	-0.2	-0.19	0.79	0.02	0.77	-0.23	-0.45	-0.2	-0.34	-0.44	0.9	-0.24	0.75	0.21	-0.13	0.27	0.44		-0.37
Extraordinary Items	-0.49	-0.46	-0.15	-0.22	-0.09	-0.18	-0.19	-0.65	-0.16	-0.68	-0.19	0.2	-0.15	-0.19	0.65	-0.1	0.23	-0.2	-0.79	-0.62	0.43	-0.88	-0.37

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.8B	2.9B	4.1B	5.3B	4.9B	5.2B
Interest Expense	1.4B	1.3B	1.3B	1.3B	1.6B	1.7B
Total Revenue	24.4B	26.6B	37.4B	44.4B	45.8B	24.2B
Gross Profit	19.5B	21.3B	25.0B	32.0B	37.8B	19.9B
Other Operating Expenses	21.2B	21.5B	36.4B	40.6B	37.6B	19.0B
Operating Income	2.9B	5.2B	1.1B	3.8B	8.2B	5.0B
Ebit	3.0B	5.2B	1.0B	3.8B	8.5B	5.1B
Research Development	6.0B	6.0B	9.7B	9.8B	10.9B	11.5B
Ebitda	6.7B	8.1B	5.1B	9.1B	13.4B	7.3B
Total Operating Expenses	16.3B	16.2B	23.9B	28.2B	29.6B	31.1B
Income Before Tax	1.5B	3.9B	(265M)	2.5B	6.9B	4.5B
Total Other Income Expense Net	(1.4B)	(1.2B)	(1.3B)	(1.3B)	(1.3B)	(1.2B)
Net Income	1.3B	3.2B	112M	3.3B	6.0B	3.5B
Income Tax Expense	321M	772M	(380M)	(792M)	938M	729.2M
Selling General Administrative	11.7B	11.7B	95M	19.0B	(197M)	(187.2M)
Cost Of Revenue	4.9B	5.3B	12.4B	12.4B	8.0B	6.5B
Net Income Applicable To Common Shares	1.3B	3.2B	112M	3.3B	3.0B	3.2B
Minority Interest	1.5B	16M	(3M)	(5M)	(6M)	(5.7M)
Selling And Marketing Expenses	11.8B	11.7B	15.7B	19.0B	18.2B	11.9B
Net Income From Continuing Ops	1.2B	3.1B	115M	3.3B	6.0B	6.3B
Tax Provision	321M	772M	(380M)	(792M)	938M	984.9M
Net Interest Income	(1.2B)	(1.2B)	(1.3B)	(1.3B)	(1.3B)	(1.4B)
Interest Income	132M	145M	87M	95M	301M	316.1M
Reconciled Depreciation	3.8B	3.1B	6.5B	5.5B	4.9B	4.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in AstraZeneca Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Historical Income Statement

About AstraZeneca Income Statement Analysis

AstraZeneca PLC Income Statement Chart

Total Revenue

Other Operating Expenses

AstraZeneca PLC income statement Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC income statement Accounts

Also Currently Popular

Other Information on Investing in AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Ebit
Net Income	+ 0.99	Ebit
Net Income	+ 0.99	Income Before Tax

Extraordinary Items	- 0.88	Interest Income
Total Other Income Expense Net	- 0.88	Interest Expense
Extraordinary Items	- 0.79	Net Income From Continuing Ops
Extraordinary Items	- 0.68	Total Operating Expenses
Extraordinary Items	- 0.65	Research Development
Extraordinary Items	- 0.62	Tax Provision